Enfortumab Vedotin consistently improves PFS and OS compared to chemotherapy, regardless of dose modifications, ⭕️ Dose modifications help manage EV-related side effects without compromising the treatment’s effectiveness. ⭕️Start with 1.25 mg/kg, reduce if needed! @asco #asco24

Biomarker data from KN426 (axi/pembro vs sunitinib) in 1st line RCC. Within arm analysis show T cell signature ⬆️ responses for axi/pembro while angiogenic signatures ⬆️ sunitinib.RNA clusters didn’t define winners. DNA/PD-L1 not helpful. VEGF in both arms is problematic #ASCO24

The javelin 100 maintenance avelumab trial include ~100 patients who did not have pure UC (such as squamous differentiation). While overall outcome of these patients might be slightly worse avelumab was associated with benifit, supporting its broad use in UC #ASCO24

Interesting data from Maluf LACOG - Latin American Cooperative Oncology Group #HERCULES trial in penile cancer. 40%ORR makes a compelling comparison with established TIP regimen. PFS/OS data still poor. HPV confirms to be the Bmk of penile CA. ASCO #ASCO24 Global Society of Rare GU Tumors Philippe spiess Curtis Pettaway, MD

Masterful presentation by #FernandoMaluf presenting results of the #HERCULES LACOG 2018 trial #ASCO24 ⚪️ First trial to demonstrate efficacy of ICI in advanced penile cancer w/ manageable safety profile (cORR 42.4% by CR) ⚪️ Pembro + chemo as new Tx option for pts w/ advanced

Relevant presentation by Eva Katharina Masel on integrating #palliative care into the management of GU cancers! #ASCO24 MedUni Wien ASCO OncoAlert

40% response rate for chemo +pembro in advanced penile cancer #ASCO24 HPV16-positive (cORR 55.6%) and TMB-high (cORR 75%) potentially enrich. Great investigator initiated study from LACOG and Fernando Maluf 

The IBCG Quick Guide to Non-Muscle Invasive Bladder Cancer (NMIBC) Bladder Cancer Quick Reference Sheet summarizes essential details on diagnosis, treatment options, and follow-up for NMIBC all in one convenient place #AUA24 #EAU24 #IBCG24 #ASCO24 Designed by Amanda Myers

Le interviste del Congresso Nazionale #AIOMGiovani 2024 sono disponibili su AIOM Tv: youtube.com/playlist?list=… rossanaberardi Filippo Pietrantonio saverio cinieri Lorenzo Gerratana Marco Maruzzo Alberto Puccini Lorenzo Belluomini Roberto Borea, MD Angela Toss #AIOMTv #giovanioncologi

🚨 Exciting Update! 🚨 Our new EVITA (EV Ineligible criTeriA) criteria for identifying patients ineligible for the EV/Pembro combo in #metastaticurothelialcarcinoma has just been published in European Urology!!!! This breakthrough could significantly reshape daily clinical practice!

Tivozanib +/- nivolumab in IO pretreated M1 renal cancer showed retreatment with IO makes absolutely no difference. This is on top of CONTACT3 which showed the same thing.We need to stop retreating with IO.These data apply in the post adjuvant setting too without data #ESMO2024

Chiara Ciccarese rocked the stage presenting preliminary data of TACITO trial investigating #FMT on #mRCC. Primary endpoint 1-y PFS met and no safety issues. Thanks to Gianluca Ianiro leading the gastroenterology team & all coinvesigators for this significant achievement. OncoAlert

The 1st disitimab Vedotin (HER-2 MMAE ADC) & pembro showing 1st line response rates of 75% in HER 1-3+ UC. Toxicity profile looks distinct from EV (fatigue>skin). There is a global randomised phase 3 of DV & pembro vs standard chemotherapy. #ESMO24 Jonathan Rosenberg MD Matt Galsky

Nectin-4 is the target for Enfortumab Vedotin and is widely expressed in UC (median 275/300) . EV302 is 1st randomised trial to explore its relationship with response. IHC results show no clear relationship between Nectin-4 and outcome (RR,PFS,OS) or PD-L1 #ESMO2024

Neoadjuvant chemotherapy plus durvalumab, followed by adjuvant durvalumab after cystectomy, led to event-free survival superior to that with neoadjuvant chemotherapy followed by cystectomy alone. Full NIAGARA trial results: nej.md/4gmAqk3 #ESMO24

Perioperative durvalumab + neoadjuvant chemo & cystectomy in operable bladder cancer significantly delays (HR 0.68) event free survival and a 25% reduction in the risk of death. 10% ⬆️ pCR. It’s the 1st time immune therapy has an OS benefit in muscle invasive UC #ESM024 NEJM

Wonderful day at the #SIURO2024 congress in Bologna! A great society that brings together Italian oncologists Marco Maruzzo,Roberto Iacovelli Daniele Raggi urologists Paolo Gontero,Filippo Pederzoli and radiotherapists, followed by an unforgettable evening with friends associazionepalinuro

TALAPRO-2 Final OS Data: TALA+ENZA in 1L mCRPC Neeraj Agarwal, MD, FASCO 👏👏👏 🧬TALA+ENZA significantly improves OS vs ENZA alone in all-comer mCRPC, rPFS benefit sustain. No new safety signals. @asco @oncoalert #GU25 #cancer #oncology Michael Serzan, MD Enrique Grande Cristiane D Bergerot

My dear friend Neeraj Agarwal, MD, FASCO presenting #TALAPRO2 final OS analysis: TALA + ENZA significantly improved OS vs PBO + ENZA in 1L mCRPC (HR 0.796). rPFS benefit sustained (HR 0.667). Safety consistent with prior reports. Phenomenal! André P. Fay #KarimFizazi ASCO #GU25 OncoAlert

Updates of STOPCAP? #GU25 STOPCAP shares 7 trials identifying who benefits from ARPi in mHSPC… ✅Benefit of intensification treatment of #mHSPC with ARPi in most patients in OS and PFS Keep in mind… 📌Young patients have clear benefit from all ARPIs 📌More data needed in